Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder

Sean M. Murphy, Daniel Polsky, Joshua Lee, Peter D. Friedmann, Timothy W. Kinlock, Edward V. Nunes, Richard J. Bonnie, Michael Gordon, Donna T. Chen, Tamara Y. Boney, Charles P. O'Brien

Research output: Contribution to journalArticle

Abstract

Background and Aims: Criminal justice-involved individuals are highly susceptible to opioid relapse and overdose-related deaths. In a recent randomized trial, we demonstrated the effectiveness of extended-release naltrexone (XR-NTX; Vivitrol®) in preventing opioid relapse among criminal justice-involved US adults with a history of opioid use disorder. The cost of XR-NTX may be a significant barrier to adoption. Thus, it is important to account for improved quality of life and downstream cost-offsets. Our aims were to (1) estimate the incremental cost per quality-adjusted life-year (QALY) gained for XR-NTX versus treatment as usual (TAU) and evaluate it relative to generally accepted value thresholds; and (2) estimate the incremental cost per additional year of opioid abstinence. Design: Economic evaluation of the aforementioned trial from the taxpayer perspective. Participants were randomized to 25 weeks of XR-NTX injections or TAU; follow-up occurred at 52 and 78 weeks. Setting: Five study sites in the US Northeast corridor. Participants: A total of 308 participants were randomized to XR-NTX (n = 153) or TAU (n = 155). Measurements: Incremental costs relative to incremental economic and clinical effectiveness measures, QALYs and abstinent years, respectively. Findings: The 25-week cost per QALY and abstinent-year figures were $162 150 and $46 329, respectively. The 78-week figures were $76 400/QALY and $16 371/abstinent year. At 25 weeks, we can be 10% certain that XR-NTX is cost-effective at a value threshold of $100 000/QALY and 62% certain at $200 000/QALY. At 78 weeks, the cost-effectiveness probabilities are 59% at $100 000/QALY and 76% at $200 000/QALY. We can be 95% confident that the intervention would be considered ‘good value’ at $90 000/abstinent year at 25 weeks and $500/abstinent year at 78 weeks. Conclusions: While extended-release naltrexone appears to be effective in increasing both quality-adjusted life-years (QALYs) and abstinence, it does not appear to be cost-effective using generally accepted value thresholds for QALYs, due to the high price of the injection.

Original languageEnglish (US)
Pages (from-to)1440-1450
Number of pages11
JournalAddiction
Volume112
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Naltrexone
Criminal Law
Quality-Adjusted Life Years
Opioid Analgesics
Cost-Benefit Analysis
Recurrence
Costs and Cost Analysis
Injections
Therapeutics
Economics
Quality of Life

Keywords

  • Cost-effectiveness
  • criminal justice populations
  • extended release naltrexone
  • opioid use disorder
  • quality-adjusted life-years
  • time abstinent

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health

Cite this

Murphy, S. M., Polsky, D., Lee, J., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., ... O'Brien, C. P. (2017). Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. Addiction, 112(8), 1440-1450. https://doi.org/10.1111/add.13807

Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. / Murphy, Sean M.; Polsky, Daniel; Lee, Joshua; Friedmann, Peter D.; Kinlock, Timothy W.; Nunes, Edward V.; Bonnie, Richard J.; Gordon, Michael; Chen, Donna T.; Boney, Tamara Y.; O'Brien, Charles P.

In: Addiction, Vol. 112, No. 8, 01.08.2017, p. 1440-1450.

Research output: Contribution to journalArticle

Murphy, SM, Polsky, D, Lee, J, Friedmann, PD, Kinlock, TW, Nunes, EV, Bonnie, RJ, Gordon, M, Chen, DT, Boney, TY & O'Brien, CP 2017, 'Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder', Addiction, vol. 112, no. 8, pp. 1440-1450. https://doi.org/10.1111/add.13807
Murphy, Sean M. ; Polsky, Daniel ; Lee, Joshua ; Friedmann, Peter D. ; Kinlock, Timothy W. ; Nunes, Edward V. ; Bonnie, Richard J. ; Gordon, Michael ; Chen, Donna T. ; Boney, Tamara Y. ; O'Brien, Charles P. / Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. In: Addiction. 2017 ; Vol. 112, No. 8. pp. 1440-1450.
@article{41a19d794d2c4b3994963597172649b5,
title = "Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder",
abstract = "Background and Aims: Criminal justice-involved individuals are highly susceptible to opioid relapse and overdose-related deaths. In a recent randomized trial, we demonstrated the effectiveness of extended-release naltrexone (XR-NTX; Vivitrol{\circledR}) in preventing opioid relapse among criminal justice-involved US adults with a history of opioid use disorder. The cost of XR-NTX may be a significant barrier to adoption. Thus, it is important to account for improved quality of life and downstream cost-offsets. Our aims were to (1) estimate the incremental cost per quality-adjusted life-year (QALY) gained for XR-NTX versus treatment as usual (TAU) and evaluate it relative to generally accepted value thresholds; and (2) estimate the incremental cost per additional year of opioid abstinence. Design: Economic evaluation of the aforementioned trial from the taxpayer perspective. Participants were randomized to 25 weeks of XR-NTX injections or TAU; follow-up occurred at 52 and 78 weeks. Setting: Five study sites in the US Northeast corridor. Participants: A total of 308 participants were randomized to XR-NTX (n = 153) or TAU (n = 155). Measurements: Incremental costs relative to incremental economic and clinical effectiveness measures, QALYs and abstinent years, respectively. Findings: The 25-week cost per QALY and abstinent-year figures were $162 150 and $46 329, respectively. The 78-week figures were $76 400/QALY and $16 371/abstinent year. At 25 weeks, we can be 10{\%} certain that XR-NTX is cost-effective at a value threshold of $100 000/QALY and 62{\%} certain at $200 000/QALY. At 78 weeks, the cost-effectiveness probabilities are 59{\%} at $100 000/QALY and 76{\%} at $200 000/QALY. We can be 95{\%} confident that the intervention would be considered ‘good value’ at $90 000/abstinent year at 25 weeks and $500/abstinent year at 78 weeks. Conclusions: While extended-release naltrexone appears to be effective in increasing both quality-adjusted life-years (QALYs) and abstinence, it does not appear to be cost-effective using generally accepted value thresholds for QALYs, due to the high price of the injection.",
keywords = "Cost-effectiveness, criminal justice populations, extended release naltrexone, opioid use disorder, quality-adjusted life-years, time abstinent",
author = "Murphy, {Sean M.} and Daniel Polsky and Joshua Lee and Friedmann, {Peter D.} and Kinlock, {Timothy W.} and Nunes, {Edward V.} and Bonnie, {Richard J.} and Michael Gordon and Chen, {Donna T.} and Boney, {Tamara Y.} and O'Brien, {Charles P.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1111/add.13807",
language = "English (US)",
volume = "112",
pages = "1440--1450",
journal = "Addiction",
issn = "0965-2140",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder

AU - Murphy, Sean M.

AU - Polsky, Daniel

AU - Lee, Joshua

AU - Friedmann, Peter D.

AU - Kinlock, Timothy W.

AU - Nunes, Edward V.

AU - Bonnie, Richard J.

AU - Gordon, Michael

AU - Chen, Donna T.

AU - Boney, Tamara Y.

AU - O'Brien, Charles P.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background and Aims: Criminal justice-involved individuals are highly susceptible to opioid relapse and overdose-related deaths. In a recent randomized trial, we demonstrated the effectiveness of extended-release naltrexone (XR-NTX; Vivitrol®) in preventing opioid relapse among criminal justice-involved US adults with a history of opioid use disorder. The cost of XR-NTX may be a significant barrier to adoption. Thus, it is important to account for improved quality of life and downstream cost-offsets. Our aims were to (1) estimate the incremental cost per quality-adjusted life-year (QALY) gained for XR-NTX versus treatment as usual (TAU) and evaluate it relative to generally accepted value thresholds; and (2) estimate the incremental cost per additional year of opioid abstinence. Design: Economic evaluation of the aforementioned trial from the taxpayer perspective. Participants were randomized to 25 weeks of XR-NTX injections or TAU; follow-up occurred at 52 and 78 weeks. Setting: Five study sites in the US Northeast corridor. Participants: A total of 308 participants were randomized to XR-NTX (n = 153) or TAU (n = 155). Measurements: Incremental costs relative to incremental economic and clinical effectiveness measures, QALYs and abstinent years, respectively. Findings: The 25-week cost per QALY and abstinent-year figures were $162 150 and $46 329, respectively. The 78-week figures were $76 400/QALY and $16 371/abstinent year. At 25 weeks, we can be 10% certain that XR-NTX is cost-effective at a value threshold of $100 000/QALY and 62% certain at $200 000/QALY. At 78 weeks, the cost-effectiveness probabilities are 59% at $100 000/QALY and 76% at $200 000/QALY. We can be 95% confident that the intervention would be considered ‘good value’ at $90 000/abstinent year at 25 weeks and $500/abstinent year at 78 weeks. Conclusions: While extended-release naltrexone appears to be effective in increasing both quality-adjusted life-years (QALYs) and abstinence, it does not appear to be cost-effective using generally accepted value thresholds for QALYs, due to the high price of the injection.

AB - Background and Aims: Criminal justice-involved individuals are highly susceptible to opioid relapse and overdose-related deaths. In a recent randomized trial, we demonstrated the effectiveness of extended-release naltrexone (XR-NTX; Vivitrol®) in preventing opioid relapse among criminal justice-involved US adults with a history of opioid use disorder. The cost of XR-NTX may be a significant barrier to adoption. Thus, it is important to account for improved quality of life and downstream cost-offsets. Our aims were to (1) estimate the incremental cost per quality-adjusted life-year (QALY) gained for XR-NTX versus treatment as usual (TAU) and evaluate it relative to generally accepted value thresholds; and (2) estimate the incremental cost per additional year of opioid abstinence. Design: Economic evaluation of the aforementioned trial from the taxpayer perspective. Participants were randomized to 25 weeks of XR-NTX injections or TAU; follow-up occurred at 52 and 78 weeks. Setting: Five study sites in the US Northeast corridor. Participants: A total of 308 participants were randomized to XR-NTX (n = 153) or TAU (n = 155). Measurements: Incremental costs relative to incremental economic and clinical effectiveness measures, QALYs and abstinent years, respectively. Findings: The 25-week cost per QALY and abstinent-year figures were $162 150 and $46 329, respectively. The 78-week figures were $76 400/QALY and $16 371/abstinent year. At 25 weeks, we can be 10% certain that XR-NTX is cost-effective at a value threshold of $100 000/QALY and 62% certain at $200 000/QALY. At 78 weeks, the cost-effectiveness probabilities are 59% at $100 000/QALY and 76% at $200 000/QALY. We can be 95% confident that the intervention would be considered ‘good value’ at $90 000/abstinent year at 25 weeks and $500/abstinent year at 78 weeks. Conclusions: While extended-release naltrexone appears to be effective in increasing both quality-adjusted life-years (QALYs) and abstinence, it does not appear to be cost-effective using generally accepted value thresholds for QALYs, due to the high price of the injection.

KW - Cost-effectiveness

KW - criminal justice populations

KW - extended release naltrexone

KW - opioid use disorder

KW - quality-adjusted life-years

KW - time abstinent

UR - http://www.scopus.com/inward/record.url?scp=85017456628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017456628&partnerID=8YFLogxK

U2 - 10.1111/add.13807

DO - 10.1111/add.13807

M3 - Article

C2 - 28239984

AN - SCOPUS:85017456628

VL - 112

SP - 1440

EP - 1450

JO - Addiction

JF - Addiction

SN - 0965-2140

IS - 8

ER -